Filing Details
- Accession Number:
- 0001140361-12-044717
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-10-26 10:45:59
- Reporting Period:
- 2012-10-24
- Filing Date:
- 2012-10-26
- Accepted Time:
- 2012-10-26 10:45:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1184149 | W Jonathan Ayers | One Idexx Drive Westbrook ME 04092 | Chairman, President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2012-10-24 | 20,000 | $17.14 | 376,749 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2012-10-24 | 13,926 | $96.36 | 362,823 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2012-10-24 | 1,074 | $97.12 | 361,749 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2012-10-24 | 20,000 | $0.00 | 20,000 | $17.14 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 64,164 | 2013-02-06 | No | 4 | M | Direct |
Footnotes
- The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/27/2012.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $95.96 to $96.95, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $96.96 to $97.50, inclusive.
- Grant of options to buy shares of common stock becomes exercisable as to 30,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, and 02/06/2007, and the remaining 24,164 shares on 02/06/2008.
Billionaire Hedge Funds
